Press Releases

Date Title and Summary Additional Formats
Toggle Summary Amicus Therapeutics to Host R&D Day
CRANBURY, N.J., Nov 27, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced that it will host an "R&D Day" meeting on December 19, 2007 from 4:30 to 7:00 PM at the Four Seasons Hotel in New York City.
View HTML
Toggle Summary Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
CRANBURY, N.J., Nov 20, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, President and Chief Executive Officer, will present a corporate update at the Lazard Capital Markets Fourth Annual Healthcare Conference in New
View HTML
Toggle Summary Amicus Therapeutics and Shire plc Enter Into $440 Million ex-US Licensing Agreement to Develop and Commercialize Amigal(TM), Plicera(TM) and At2220
Amicus to Host Conference Call at 8:00 A.M. Eastern Time
View HTML
Toggle Summary Amicus Therapeutics Announces Third Quarter 2007 Financial Results
CRANBURY, N.J., Oct 31, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company developing small molecule, orally-active pharmacological chaperones for the treatment of human genetic diseases, today announced financial results for the
View HTML
Toggle Summary Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease CRANBURY, N.J., October 23, 2007 -- Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of a range of
View HTML
Toggle Summary Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
CRANBURY, N.J., Sept 18, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced that it plans to present the results of Phase 1 studies of AT2220 (1-deoxynojirimycin HCl) for Pompe Disease at the American Society of Human Genetics (ASHG) Annual
View HTML
Toggle Summary Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
CRANBURY, N.J., Sept 12, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John Crowley, President and Chief Executive Officer, will present a corporate update at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
View HTML
Toggle Summary Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Amicus Therapeutics Announces Second Quarter 2007 Financial Results Cranbury, NJ, August 2, 2007 - Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company developing small molecule, orally-delivered pharmacological chaperones for the treatment of human genetic diseases, today announced
View HTML
Toggle Summary Amicus Therapeutics Announces Pricing of Initial Public Offering of 5,000,000 Shares of Common Stock
CRANBURY, N.J., May 31, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics (Nasdaq: FOLD) announced today the pricing of its initial public offering (IPO) of 5,000,000 shares of its common stock at a public offering price of $15.00 per share.
View HTML
Toggle Summary Amicus Therapeutics (FOLD) President and Chief Executive Officer to Ring the NASDAQ Stock Market Closing Bell
Company to Celebrate Initial Public Offering On NASDAQ
View HTML